Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 1, 2026

NVIDIA Unveils Vera, the CPU for Agents

View original at finance.yahoo.com
NVIDIA Unveils Vera, the CPU for Agents NVIDIA 1.8x Faster Than x86 Processors to Drive Diverse Workloads Across Industries, Generating More Data Center Token Revenue NVIDIA Vera CPU RackNVIDIA Vera is a new class of processor enabling 1.8x faster task completion compared with x86 CPUs.·GlobeNewswire Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Vera serves as the CPU powering standalone Vera servers, NVIDIA Vera Rubin systems, and Vera BlueField-4 STX AI storage platforms

    60% confidence

  • AI agents will be the largest users of computing; Vera is the first CPU designed for that future, built to run agentic AI at hyperscale with extraordinary performance, efficiency and programmability

    60% confidence

  • The NYSE processes more than 1.1 trillion messages per day and will scale capacity while optimizing latency using NVIDIA Vera CPUs in collaboration with Redpanda and HPE

    60% confidence

  • NYSE's focus is to optimize the latency, throughput and reliability of its unrivaled infrastructure

    60% confidence

  • Vera drives more data center token revenue compared to x86 alternatives

    60% confidence

  • NVIDIA Vera CPU achieves 1.8x faster task completion compared with x86 CPUs

    60% confidence

  • NVIDIA Grace CPUs have achieved nearly 2.5 million shipments to date

    60% confidence

  • NVIDIA Vera CPU is now in full production

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
NVIDIA Unveils Vera, the CPU for Agents — Source | Via News | Via News